Information on Gibson Oncology’s important new developments in Brain Cancer-coming soon...
- Orphan Drug Designation (ODD) from the FDA for both Glioblastoma and
multiple types of Gliomas.
- Finalizing discussions with the NIH on conducting Phase II Clinical Trials in
GBM.
- Clinical trial based on basic research performed by the NIH, by Purdue
University, by the Robert Preston Tisch Brain Tumor Center at Duke
University, and by Gibson Oncology.
- Multiple Phase I FDA clinical trials completed by the National Cancer
Institute.
Gibson Oncology will release more specific information when granted permission from our partners.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Miami, Fl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gibsononcology.com
- HQ
- MIAMI, FL
Gibson Oncology, Llc Questions
Gibson Oncology, Llc's website is gibsononcology.com
Gibson Oncology, Llc's LinkedIn profile is https://www.linkedin.com/company/gibson-oncology
Gibson Oncology, Llc has
5 employees.
View email and phone details for 5
employees at Gibson Oncology, Llc.
Gibson Oncology, Llc's industry is
Biotechnology Research
Gibson Oncology, Llc's top competitors are
Nutra Pharma Corporation,
Kanpecia Biotech Llc,
Curative Biotech,
Diverse Biotech,
Afr Oncology,
Trippbio,
Neotherma Oncology,
Jupiter Neurosciences, Inc.,
Aptus Bioscience,
New/era/mabs.
Gibson Oncology, Llc's categories are Biotechnology Research
Gibson Oncology, Llc's founding year is 2018
